Estimate of Medicare Part D Costs After Accounting for Manufacturer Rebates

In recent years, the cost of medicines in the U.S. has been the subject of much public discussion due to its pricing process complexity. This report analyzes twelve high volume therapy classes in Medicare Part D, measures the costs for 30 days of therapy for branded medicines in each class, and estimates net cost to Part D plans and patients including estimates of negotiated discounts and rebates. This study was conducted independently by the QuintilesIMS Institute with funding support from the Pharmaceutical Research and Manufacturers of America (PhRMA).

Download Report